Flemming Ørnskov, Galderma CEO
Galderma drug passes PhIII in rare skin disease, setting the stage for approval request
Dermatology behemoth Galderma is one step closer to regulators’ doorsteps for a monoclonal antibody it licensed from Chugai Pharmaceutical after a Phase III readout Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.